PRWeb.com Press Release Feed - PRWeb Press Release Account Feed http://www.rsspad.com/rss2a/101398.xml PRWeb.com Press Release Feed - Press Releases en xml@emediawire.com xml@emediawire.com 30 Vitalea Science Completes Dermal Distribution Microdose Study http://www.prweb.com/releases/2007/06/prweb531698.htm Vitalea advanced the boundaries of Accelerator Mass Spectrometry (AMS) applications by measuring the test compound in exhaled air taken from patients' breath and by determining distribution of the compound in skin. This study establishes improved capabilities to better determine ADME of new drugs, nutrients and chemical products. (PRWeb Jun 8, 2007)

Read the full story at http://www.prweb.com/releases/2007/06/prweb531698.htm

]]> Fri, 08 Jun 2007 07:00:00 GMT http://www.prweb.com/releases/2007/06/prweb531698.htm Vitalea Science Expands its Scientific Advisory Board, Expands Microdosing to Environmental Fate and Metabolism of Agricultural and Industrial Chemicals http://www.prweb.com/releases/2007/05/prweb526302.htm Dr. Luis Ruzo of PTRL West joins the Scientific Advisory Board (SAB) of Vitalea Science, bringing expanded perspectives for applying microdosing and accelerator mass spectrometry to developing pharmaceutical, agrochemical and industrial chemicals. (PRWeb May 16, 2007)

Read the full story at http://www.prweb.com/releases/2007/05/prweb526302.htm

]]> Wed, 16 May 2007 07:00:00 GMT http://www.prweb.com/releases/2007/05/prweb526302.htm Vitalea Science Announces Key Addition to its Scientific Advisory Board in Microdosing for Pediatric Pharmacology and HIV Research http://www.prweb.com/releases/2007/05/prweb525113.htm Vitalea Science announces the addition of Dr. Edmund Capparelli to its Scientific Advisory Board. Dr. Capparelli is a leading HIV and pediatric pharmacologist at the University of California, San Diego (UCSD). He is Director of the UCSD Pediatric Pharmacology Research Unit, which focuses on protocols to safely evaluate drugs for pediatric populations. Vitalea's microdosing technology enables a patient-friendly, FDA-endorsed approach to safely evaluate drugs in a wide range of patients, with specific advantages for pediatric drugs. (PRWeb May 10, 2007)

Read the full story at http://www.prweb.com/releases/2007/05/prweb525113.htm

]]> Thu, 10 May 2007 07:00:00 GMT http://www.prweb.com/releases/2007/05/prweb525113.htm Collaboration Between the Paul Scherrer Institut and Vitalea Science Brings Compact Accelerator Mass Spectrometer to the Pharmaceutical Industry http://www.prweb.com/releases/2007/03/prweb510888.htm The Bio-MICADAS is a next-generation, high throughput AMS instrument designed to meet the specific needs of clinical research. It was developed through a collaboration between the Paul Scherrer Institut of Zurich, Switzerland and Vitalea to meet strict clinical requirements for drug development. It provides several new options for clinical drug development such as Phase 0 microdosing and Phase 1 ADME without radioactivity. (PRWeb Mar 12, 2007)

Read the full story at http://www.prweb.com/releases/2007/03/prweb510888.htm

]]> Mon, 12 Mar 2007 07:00:00 GMT http://www.prweb.com/releases/2007/03/prweb510888.htm New Tools Developed by Vitalea Science for Pediatric Pharmacology Use Microdose and Accelerator Mass Spectrometry http://www.prweb.com/releases/2007/02/prweb505093.htm Vitalea Science announces the development and testing of assays to quantify intracellular uptake and DNA incorporation of the active metabolite of an anti-HIV drug that can be applied to children and neonates. (PRWeb Feb 15, 2007)

Read the full story at http://www.prweb.com/releases/2007/02/prweb505093.htm

]]> Thu, 15 Feb 2007 08:00:00 GMT http://www.prweb.com/releases/2007/02/prweb505093.htm Vitalea Science and Paul Scherrer Institute (PSI) Announce a Technological Alliance that will Eliminate Hazardous Radiation from Pharmaceutical Studies http://www.prweb.com/releases/2006/09/prweb435283.htm A compact Accelerator has been developed by Paul Scherrer Institute of Switzerland with support from Vitalea Science of California that will change they way drugs are tested in clinical trials. The developed instrument, the BioMicadas, a compact particle accelerator stands to remove radioactivity from clinical drug trials. (PRWeb Sep 12, 2006)

Read the full story at http://www.prweb.com/releases/2006/09/prweb435283.htm

]]> Tue, 12 Sep 2006 07:00:00 GMT http://www.prweb.com/releases/2006/09/prweb435283.htm An Alternative for "Alternative Medicine"? How atomic physics can revolutionize the supplement industry. http://www.prweb.com/releases/2004/11/prweb178340.htm Progess in our understanding of the health benefits of nutritional and botanical supplements has been slow. Today, Vitalea Science, debuts technological platform that can answer many of the lingering questions concerning the role of these products in human health and disease. The technology, Accelerator Mass Spectrometry, was developed for atomic physics, but will now reinvigorate supplement research at a level of detail that was previously only available to the pharmaceutical industry. (PRWeb Nov 16, 2004)

Read the full story at http://www.prweb.com/releases/2004/11/prweb178340.htm

]]> Tue, 16 Nov 2004 08:00:00 GMT http://www.prweb.com/releases/2004/11/prweb178340.htm Vitalea Science, Inc. Offers Calcium-41/Accelerator Mass Spectrometry Services for Drug Efficacy Studies in the Treatment of Osteoporosis. http://www.prweb.com/releases/2004/10/prweb169950.htm Osteoporosis is characterized by a decrease in bone density, which results in an increased risk of fractures. Quantitive tracer methods using a heavy isotope of calcium, calcium-41, coupled with Accelerator Mass Spectrometry detection allow the rate of calcium bone loss, and the effectiveness of treatments to prevent this loss, to be accurately monitored. (PRWeb Oct 20, 2004)

Read the full story at http://www.prweb.com/releases/2004/10/prweb169950.htm

]]> Wed, 20 Oct 2004 07:00:00 GMT http://www.prweb.com/releases/2004/10/prweb169950.htm Vitalea Science Offers Microdose Services – A Concept That Improves Drug Development and Serves as Alternative to Animal Testing http://www.prweb.com/releases/2004/07/prweb141358.htm Vitalea Science offers a new technological platform that will shave years off of the drug development process, enabling the early testing of promising new drugs in people. The effect will be to reduce the cost of new drugs and reduce the number of laboratory animals sacrificed for drug development. (PRWeb Jul 15, 2004)

Read the full story at http://www.prweb.com/releases/2004/07/prweb141358.htm

]]> Thu, 15 Jul 2004 07:00:00 GMT http://www.prweb.com/releases/2004/07/prweb141358.htm